Abstract
Aims The Naviswiss system (Naviswiss AG, Brugg, Switzerland) is a handheld imageless navigation device used to improve the accuracy of implant positioning in total hip arthroplasty (THA). However, clinical data for leg length discrepancy and femoral offset is lacking, and the validity of the system has not been reported for patients undergoing THA in the lateral decubitus position. This study aimed to report the accuracy of the device in this patient population.
Methods Patients underwent THA in the lateral decubitus position by a single surgeon. Component positioning measured by the device intraoperatively was compared to postoperative measurements on computed tomography (CT) scans. Agreement between the navigation system and postoperative measurements was reported with respect to acetabular cup inclination, acetabular cup version, femoral offset and leg length discrepancy.
Results The mean difference between intraoperative and postoperative CT measurements was within 2° for angular measurements and 2mm for leg length. Absolute differences for the two indices were within 5° and 4mm. Mean bias was 1-2° overestimation for cup orientation and up to 2mm overestimation for leg length change, but 95% limits of agreement did not exceed absolute thresholds of 10° and 10mm, especially after correction for bias. Four cases (12%) were declared intraoperatively for issues with fixation on the greater trochanter. While inclusion of these cases generated acceptable accuracy overall, their omission improved between-case variability in accuracy and reduced the LOA for both offset and leg length.
Conclusions The accuracy of the Naviswiss system falls within clinically acceptable recommendations for acetabular cup placement, femoral offset and length length. The system could be further improved with regression-based bias correction.
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare the following: CS and MF are employed by EBM Analytics, who were contracted by Naviwsiss AG to assist with completion of protocol manuscript and data analysis for study of same device (related to submitted work). In the past 36 months, EBM Analytics has received grants or contracts from OSSIS Ltd, Headsafe Ltd, DePuy Synthes Mitek Sports Medicine and Exactech Ltd for work unrelated to the submitted manuscript. CS is a shareholder in EBM Analytics. DL received financial support from Naviswiss AG for completion of this study and support from Medivation for the image analysis component of this study. In the past 36 months, DL declares the following unrelated to the current work: grants or contracts from Zimmer Biomet and DePuy; royalties from Zimmer Biomet and DePuy; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Zimmer Biomet, DePuy and LifeHealthCare; support for attending meetings or travel from Zimmer Biomet, DePuy, Enovis; patent with DePuy, unpaid leadership roles with the Queensland AOA and the Asia Pacific Arthroplasty Society; stock in 360 MedCare and Naviwswiss AG; and an unpaid consultancy with Naviswiss AG. TS's employer was contracted by Naviswiss AG to assist with the completion of the current study. TS additionally declares stock in Naviswiss AG.
Clinical Trial
ACTRN12620000873921
Funding Statement
This work was funded by Naviswiss AG. CS and MF declare a relationship through their employment (EBM Analytics) with the sponsor through a paid consultancy. TS declares a relationship through their employment (Medivation) with the sponsor through a paid consultancy. DL declares a relationship with the sponsor as an unpaid consultant to Naviswiss AG.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Human Research Ethics Committee of Ramsay Health Care Queensland gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Upon reasonable request to the authors, only de-identified data (i.e. data with sensitive and personal information removed), will be provided as per the ANDS Publishing and Sharing Sensitive Data Guide.
